Estudo sobre os efeitos anticancerígenos da melatonina em tumores de pulmão (NSCLC) e suas possíveis aplicações terapêuticas

Neste estudo, publicado em Oncotarget foram analisados, com resultados positivos, os efeitos anticancerígenos da melatonina no carcinoma de células não pequenas. O câncer de pulmão de células não pequenas (NSCLC) é também chamado como adenocarcinoma ou carcinoma de células escamosas. De acordo com a American Cancer Society (ACS), é o câncer de pulmão mais comum, o que corresponde a 85-90% de todos os cânceres de pulmão diagnosticados (dados ACS, 2012). Não está crescendo tão rapido como carcinoma de células pequenas.

Melatonin as a potential anticarcinogen for non-small-cell lung cancer.

Oncotarget. 2016 Apr 18;

Authors: Ma Z, Yang Y, Fan C, Han J, Wang D, Di S, Hu W, Liu D, Li X, Reiter RJ, Yan X

Non-small-cell lung cancer (NSCLC) is a leading cause of death from cancer worldwide. Melatonin, an idoleamine discovered in the pineal gland, exerts pleiotropic anticancer effects against a variety of cancer types. In particular, melatonin may be an important anticancer drug in the treatment of NSCLC. Herein, we review the correlation between the disruption of the melatonin rhythm and NSCLC incidence; we also evaluate the evidence related to the effects of melatonin in inhibiting lung carcinogenesis. Special focus is placed on the oncostatic effects of melatonin, including anti-proliferation, induction of apoptosis, inhibition of invasion and metastasis, and enhancement of immunomodulation. We suggest the drug synergy of melatonin with radio- or chemotherapy for NSCLC could prove to be useful. Taken together, the information complied herein may serve as a comprehensive reference for the anticancer mechanisms of melatonin against NSCLC, and may be helpful for the design of future experimental research and for advancing melatonin as a therapeutic agent for NSCLC.

PMID: 27102150 [PubMed - as supplied by publisher]